Abstract
The control of gene expression is critical for metabolic engineering. The multi-copy plasmids has been widely used for high-level expression of genes. However, plasmid-based expression systems are liable to genetic instability and require a selective pressure to assure plasmid stability. In this study, we first constructed a lycopene producer Escherichia coli through promoter engineering. Saccharomyces cerevisiae mevalonate (MEV) pathway was also optimized to balance expression of the top and bottom MEV pathway by using the different strength promoters. The chromosomal heterologous expression of the optimized S. cerevisiae MEV pathway can further improved lycopene production. The final engineered strain, E. coli LYCOP 20, produced lycopene of 529.45 mg/L and 20.25 mg per gram of dry cell weight in the fed-batch culture. The engineered strain does not have a plasmid or antibiotic marker. This strategy used in this study can be applied in pathway engineering of E. coli and other bacteria.
Keywords: Escherichia coli, lycopene, promoter engineering.
Current Pharmaceutical Biotechnology
Title:Engineering of Escherichia coli for Lycopene Production Through Promoter Engineering
Volume: 16 Issue: 12
Author(s): Hong-Jie Shen, Jin-Jing Hu, Xi-Ran Li and Jian-Zhong Liu
Affiliation:
Keywords: Escherichia coli, lycopene, promoter engineering.
Abstract: The control of gene expression is critical for metabolic engineering. The multi-copy plasmids has been widely used for high-level expression of genes. However, plasmid-based expression systems are liable to genetic instability and require a selective pressure to assure plasmid stability. In this study, we first constructed a lycopene producer Escherichia coli through promoter engineering. Saccharomyces cerevisiae mevalonate (MEV) pathway was also optimized to balance expression of the top and bottom MEV pathway by using the different strength promoters. The chromosomal heterologous expression of the optimized S. cerevisiae MEV pathway can further improved lycopene production. The final engineered strain, E. coli LYCOP 20, produced lycopene of 529.45 mg/L and 20.25 mg per gram of dry cell weight in the fed-batch culture. The engineered strain does not have a plasmid or antibiotic marker. This strategy used in this study can be applied in pathway engineering of E. coli and other bacteria.
Export Options
About this article
Cite this article as:
Shen Hong-Jie, Hu Jin-Jing, Li Xi-Ran and Liu Jian-Zhong, Engineering of Escherichia coli for Lycopene Production Through Promoter Engineering, Current Pharmaceutical Biotechnology 2015; 16 (12) . https://dx.doi.org/10.2174/1389201016666150731110536
DOI https://dx.doi.org/10.2174/1389201016666150731110536 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Selection of Single Chain Antibody Fragments for Targeting Prostate Specific Membrane Antigen: A Comparison Between Cell-based and Antigen-based Approach
Protein & Peptide Letters Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders
Current Topics in Medicinal Chemistry Erythropoietin and Oxidative Stress
Current Neurovascular Research Synergistic Effect of α-Solanine and Cisplatin Induces Apoptosis and Enhances Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry DNA Drug Design for Cancer Therapy
Current Pharmaceutical Design RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy Heat Shock Protein 90 Inhibitors in Oncology
Current Proteomics Changes in and Impact of the Death Review Process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
Reviews on Recent Clinical Trials Possible Involvement of Angiogenesis in Chronic Liver Diseases: Interaction Among Renin-Angiotensin-Aldosterone System, Insulin Resistance and Oxidative Stress
Current Medicinal Chemistry Autoimmune Pancreatitis and Diagnostic Criteria
Current Immunology Reviews (Discontinued) Psoriasis in Children: A Review
Current Pediatric Reviews Mitochondrial Trifunctional Protein Defects: Molecular Basis and Novel Therapeutic Approaches
Current Drug Targets - Immune, Endocrine & Metabolic Disorders MicroRNA and Cancer: Tiny Molecules with Major Implications
Current Genomics CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges
Recent Patents on Anti-Cancer Drug Discovery Planning of External Beam Radiotherapy for Prostate Cancer Guided by PET/CT
Current Radiopharmaceuticals Editorial [Hot Topic: Targeting the IGF-I Receptor Signaling Pathway:Implications for Human Cancer Therapy (Executive Editors: A. Ciampolillo and F. Giorgino) ]
Current Pharmaceutical Design Phytochemical Informatics and Virtual Screening of Herbs Used in Chinese Medicine
Current Pharmaceutical Design Cancer Stem Cells: The Emerging Challenge of Drug Targeting
Current Medicinal Chemistry Evaluation of a New <sup>99m</sup>Tc-labeled GnRH Analogue as a Possible Imaging Agent for Prostate Cancer Detection
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design